Schwarz Stephan K W, Butterfield Noam N, Macleod Bernard A, Kim Edward Y, Franciosi Luigi G, Ries Craig R
Centre for Anesthesia and Analgesia, Department of Anesthesia, The University of British Columbia, Vancouver, British Columbia, Canada.
Can J Anaesth. 2004 Nov;51(9):892-8. doi: 10.1007/BF03018886.
To compare the measured "real world" perioperative drug cost and recovery associated with desflurane- and isoflurane-based anesthesia in short (less than one hour) ambulatory surgery.
We conducted a prospective, randomized, blinded trial with patients undergoing arthroscopic meniscectomy under general anesthesia. Following iv induction, patients received either isoflurane (group I; n = 25) or desflurane (group D; n = 20) for maintenance. The primary outcome variable was total perioperative drug cost per patient in Canadian dollars. Secondary outcome variables included volatile agent consumption and cost, adjuvant anesthetic and postanesthesia care unit (PACU) drug cost, readiness for PACU discharge, and incidence of adverse events.
Total perioperative drug cost per patient was 14.58 +/- 6.83 Canadian dollars (mean +/- standard deviation) for group I, and 21.47 +/- 5.18 Canadian dollars for group D (P < 0.001). Isoflurane consumption per patient was 6.0 +/- 3.0 mL compared to 18.6 +/- 7.7 mL for desflurane (P < 0.0001); corresponding costs were 0.83 +/- 0.42 Canadian dollars vs 7.61 +/- 3.15 Canadian dollars (P < 0.0001). There were no differences in adjuvant anesthetic or PACU drug cost. All but one patient from each group were deemed ready for PACU discharge at 15 min postoperatively (Aldrete score >or= 9). One patient in group D experienced postoperative nausea. No other adverse events were noted.
Measured total perioperative drug cost for a short ambulatory procedure (less than one hour) under general anesthesia was higher when desflurane rather than isoflurane was used for maintenance, essentially due to volatile agent cost. Desflurane use did not translate into faster PACU discharge under "real world" conditions.
比较在短时间(少于1小时)门诊手术中,与地氟烷和异氟烷麻醉相关的实测“真实世界”围手术期药物成本及恢复情况。
我们对接受全身麻醉下关节镜半月板切除术的患者进行了一项前瞻性、随机、双盲试验。静脉诱导后,患者分别接受异氟烷(I组;n = 25)或地氟烷(D组;n = 20)维持麻醉。主要结局变量是以加元计算的每位患者围手术期总药物成本。次要结局变量包括挥发性麻醉剂的消耗量及成本、辅助麻醉药和麻醉后恢复室(PACU)药物成本、准备好从PACU出院的情况以及不良事件的发生率。
I组每位患者围手术期总药物成本为14.58±6.83加元(均值±标准差),D组为21.47±5.18加元(P < 0.001)。每位患者异氟烷消耗量为6.0±3.0 mL,而地氟烷为18.6±7.7 mL(P < 0.0001);相应成本分别为0.83±0.42加元和7.61±3.15加元(P < 0.0001)。辅助麻醉药或PACU药物成本无差异。每组除一名患者外,其他所有患者在术后15分钟时均被认为准备好从PACU出院(Aldrete评分≥9)。D组有一名患者术后出现恶心。未观察到其他不良事件。
在全身麻醉下进行短时间门诊手术(少于1小时)时,若使用地氟烷而非异氟烷进行维持麻醉,实测围手术期总药物成本更高,主要原因是挥发性麻醉剂成本。在“真实世界”条件下,使用地氟烷并未使患者从PACU更快出院。